Gerhard Zolss

Title: Gerhard Zolss: Innovator in Cardio-Selective β-Blocking Agents

Introduction

Gerhard Zolss is a notable inventor based in Linz, Austria. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cardio-selective β-blocking agents. With a total of 2 patents, Zolss has demonstrated his expertise and innovation in this specialized area.

Latest Patents

Zolss's latest patents include the invention of 4-Ureido-2-acyl phenoxypropanolamine and phenoxypropylamine derivatives. These compounds are characterized by their complex chemical structures, which include various alkyl groups and functional components that contribute to their cardio-selective β-blocking action. The detailed formulations highlight the potential for these derivatives to be used in therapeutic applications, particularly in managing cardiovascular conditions.

Career Highlights

Gerhard Zolss is associated with Chemie Linz Aktiengesellschaft, a company known for its focus on chemical innovations. His work at this institution has allowed him to explore and develop new pharmaceutical compounds that have the potential to improve patient outcomes in cardiovascular health.

Collaborations

Zolss has collaborated with notable colleagues such as Heribert Pittner and Heimo Stormann-Menninger-Lerchenthal. These partnerships have likely contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Gerhard Zolss stands out as an influential inventor in the pharmaceutical industry, particularly in the realm of cardio-selective β-blocking agents. His contributions through innovative patents and collaborations reflect his commitment to advancing medical science.